Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G. Richardson, Kenneth C. Anderson, Irene M. Ghobrial et al.|Blood|2010Cited by 866
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II StudyPaul G. Richardson, Kenneth C. Anderson, Sagar Lonial et al.|Blood|2008Cited by 68
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.Paul G. Richardson, Kenneth C. Anderson, Sundar Jagannath et al.|Blood|2007Cited by 30
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.Paul G. Richardson, Kenneth C. Anderson, Sagar Lonial et al.|Blood|2009Cited by 8